RxDoctor Payments Data

Mary Ward

Family · Harlan, KYNPI 1588183156

Payments from drug & device makers

$2,092in general payments, 2019–2025

Across 55 payments — averaging $38.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Endo Pharmaceuticals Inc.$184
  • Endo USA, Inc.$110
  • GSK$80
  • Novartis$63
  • AstraZeneca$60
  • plus $392 from 14 others

What the payments were for

  • Travel & lodging$91644%
  • Food & beverage$1,17656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,092 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,074
Medicare patients
16
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$50,532
MounjaroTirzepatide45$45,937
JanuviaSitagliptin Phosphate22$18,098
GemtesaVibegron17$11,862
EliquisApixaban12$11,171
FarxigaDapagliflozin Propanediol14$10,310
XareltoRivaroxaban13$5,930
SymbicortBudesonide/Formoterol Fumarate12$3,149
Tamsulosin Hcl178$2,413
Gabapentin201$1,960
Albuterol Sulfate HfaAlbuterol Sulfate55$1,709
Levothyroxine Sodium180$1,587
Ventolin HfaAlbuterol Sulfate28$1,574
Omeprazole164$1,375
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen123$1,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$48$45,93745 claims
AstraZenecaFarxiga, Symbicort$60$13,45926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Harlan

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →